Key Drivers
- Margin strength
- Cash burn
- Negative equity
AIAI Summary
BBIO now has real commercial traction from Attruby, but the investment case hinges on whether revenue can scale fast enough to offset ongoing cash burn and a fragile capital structure without repeated dilution, making execution and financing discipline the key watchpoints.
Price Chart
Financial Metrics
Deep Analysis
Research tool. Not personalized advice.
Fundamental Analysis
Key Financial Insights:
- •Margin strength
- •Cash burn
- •Negative equity
BBIO has a strong 94% gross margin and ample cash, but persistent operating losses, negative free cash flow, weakening liquidity, and a deeply negative equity base make the outlook financially strained.
Price Behavior
Key Price Behavior Insights:
- •Momentum rollover
- •$80 support test
- •Mid-80s resistance
BBIO's rally failed after a last month high near $85.55, turning momentum negative as $80 support is tested and $84.5–$85.6 now acts as resistance.
Failed to hold the last month high near $85.55, shifting into a lower-high, lower-close pattern
Sentiment & News
Key News Insights:
- •Sales surge
- •NDA accepted
- •Offering priced
BridgeBio delivered strong commercial and regulatory momentum as Attruby sales surged, encaleret's NDA was accepted, and an oversubscribed secondary offering was priced with no proceeds to the company.
The update is modestly positive for BBIO, with growth and pipeline de-risking offsetting some concern around the shareholder secondary
Similar Companies in Healthcare
Other companies in the same sector with AI ratings